Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

NCT00389090 is registered in ClinicalTrials.gov with Keryx / AOI Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00389090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00389090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Lead sponsor
Keryx / AOI Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2006
Completion date
February 28, 2009
Enrollment
32 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, glioma, oligoastrocytoma, oligodendroglioma